Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 2/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.30 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670166 | 1.00 | NR1I2 (0.35) | NR1I2CYP2E1KDM4EHTTATM | |
| SCHEMBL15498388 | 0.88 | KDM4E (0.33) | NR1I2CYP2E1KDM4EHTTATM | |
| SCHEMBL669880 | 0.85 | RAF1 (0.36) | NR1I2CYP2E1KDM4EHTTATM | |
| SCHEMBL1960222 | 0.81 | RAF1 (0.34) | NR1I2KDM4EHTTATMRAF1 | |
| SCHEMBL1960225 | 0.81 | RAF1 (0.34) | NR1I2KDM4EHTTATMRAF1 | |
| SCHEMBL670381 | 0.81 | MEN1 (0.31) | NR1I2CYP2E1MAPK14 | |
| SCHEMBL15498396 | 0.81 | MEN1 (0.31) | NR1I2CYP2E1MAPK14 | |
| SCHEMBL669498 | 0.81 | NR1I2 (0.34) | NR1I2CYP2E1KDM4EHTTATM | |
| SCHEMBL1963295 | 0.81 | CYP2E1 (0.39) | NR1I2CYP2E1KDM4EHTTATM | |
| SCHEMBL102080 | 0.80 | CHEK1 (0.42) | NR1I2CYP2E1KDM4EHTTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2606041-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024363-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | GOT1, RNASE1, SLC10A1 | NR1I2 1347/4885CYP2E1 275/4885KDM4E 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.